HSA
CLDX icon

Hussman Strategic Advisors’s Celldex Therapeutics CLDX Stock Holding History

Hussman Strategic Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,500
Closed -$447K – 337
2020
Q4 		$447K Sell
25,500
-25,500
-50% -$459K 0.12% 239
2020
Q3 		$756K Buy
+51,000
New +$597K 0.2% 177

Other funds holding CLDX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Hussman Strategic Advisors's CLDX Position: Q1 2021 in Review

Hussman Strategic Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2021, closing a stake of 25,500 shares — an estimated $447K sold.

Hussman Strategic Advisors first reported a position in CLDX in Q3 2020 and held it in 2 quarters. The position peaked at $756K in Q3 2020. 115 funds tracked by Wall St. Rank hold CLDX as of Q1 2021.

  • Hussman Strategic Advisors reported no remaining Celldex Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Hussman Strategic Advisors sold 25,500 Celldex Therapeutics shares in Q1 2021, an estimated $447K.
  • Hussman Strategic Advisors first reported a position in Celldex Therapeutics in Q3 2020 and held it in 2 quarters.
  • Hussman Strategic Advisors's Celldex Therapeutics position peaked at $756K in Q3 2020.
  • 115 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2021.

Based on Hussman Strategic Advisors's 13F filing for Q1 2021, filed 3 May 2021.